Press Releases Incyte Corporation

Equities

INCY

US45337C1027

Real-time Estimate Cboe BZX Other stock markets 10:22:39 2024-06-11 am EDT			5-day change	1st Jan Change
58.17 ^USD	-2.07%		+0.41%	-6.34%

Jun. 10	Transcript : Incyte Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 08:00 AM
May. 23	Deutsche Bank Initiates Incyte to Hold Rating With $55 Price Target	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Incyte Announces Preliminary Results of Tender Offer	08:09am	BU
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Jun. 07	BU
Incyte Completes Acquisition of Escient Pharmaceuticals	May. 30	BU
Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings	May. 21	BU
Incyte to Present at Upcoming Investor Conference	May. 21	BU
Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress	May. 14	BU
Incyte, Squarespace rise; Chimera Investment, Amazon fall, Monday, 5/13/2024	May. 13	AQ
Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock	May. 13	BU
Incyte to Present at Upcoming Investor Conference	May. 02	BU
Incyte: Q1 Earnings Snapshot	Apr. 30	AQ
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs	Apr. 30	BU
'Shadow Trading' Verdict A Reminder For Companies To Review Insider Trading Policies And Train Insiders	Apr. 29	AQ
SEC Secures Groundbreaking Win In Shadow Trading Insider Trading Case	Apr. 27	AQ
"Shadow Trading" Is Insider Trading: Jury Establishes Liability In Historic Shadow Trading Case	Apr. 24	AQ
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists	Apr. 23	BU
SEC Wins Novel 'Shadow Trading' Trial Against Biopharma Executive	Apr. 22	AQ
Incyte to Report First Quarter Financial Results	Apr. 11	BU
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(4) - March 29, 2024	Apr. 01	AQ
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia	Apr. 01	BU
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	Mar. 29	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Incyte Corporation : Is a big change imminent?

October 26, 2023 at 10:00 am EDT